||5R01CA081220-05 Interpret this number
||Henry Ford Health System
||Colon Cancer Survivors-Medications & Risk of Recurrence
DESCRIPTION (Adapted from the Applicant's Abstract): Colorectal cancer will be
diagnosed in over 129,000 Americans in 1999. To combat this disease, new
avenues to decrease the risk of colorectal cancer, such as chemoprevention, are
being explored by researchers. Non-steroidal anti-inflammatory drugs (NSAIDs)
and hormone replacement therapy (HRT) have been shown to decrease incident
colon cancer. Little is known of their effect on persons with a history of
colon cancer which, fortunately, is a continually expanding population as
survival has been significantly improving over the last twenty years. The
objective of this epidemiologic study is to determine whether NSAIDs or HRT is
associated with recurrence or survival among individuals diagnosed with
colorectal cancer. The proposed research will establish a cohort of colorectal
cancer patients treated with curative intent and create a comprehensive
longitudinal database, including data on the ascertainment of subsequent
adenomatous polyps, colorectal cancer and survival. The specific aims are: (1)
to determine whether NSAID use deceases the risk of recurrence of colorectal
cancer; (2) to determine whether HRT use deceases the risk of recurrence of
colorectal cancer; (3) to determine whether NSAID use affects short-term
survival; and (4) to determine whether HRT use affects short-term survival. The
cohort will be established from colorectal cancer patients enrolled in two
managed care organizations, Health Alliance Plan (Detroit, MI) and
HealthPartners (Minneapolis, MN). Cohort subjects will be followed for at least
five years for new evidence of disease, recurrence and survival outcome. Using
automated pharmacy data, the timing of use and exposure to NSAIDs and HRT will
be analyzed among cancer survivors, along with potentially confounding
variables, in relation to these outcomes.
Influence of NSAID Use Among Colorectal Cancer Survivors on Cancer Outcomes.
, Jankowski M.
, Rolnick S.
, Yood M.U.
, Alford S.H.
American journal of clinical oncology, 2017 Aug; 40(4), p. 370-374.
The Schizophrenia-Associated BRD1 Gene Regulates Behavior, Neurotransmission, and Expression of Schizophrenia Risk Enriched Gene Sets in Mice.
, Christensen J.H.
, Vardya I.
, Rajkumar A.P.
, Mørk A.
, Paternoster V.
, Füchtbauer E.M.
, Pallesen J.
, Fryland T.
, Dyrvig M.
, et al.
Biological psychiatry, 2017-07-01; 82(1), p. 62-76.
Novel genetic loci underlying human intracranial volume identified through genome-wide association.
, Hibar D.P.
, Chouraki V.
, Stein J.L.
, Nyquist P.A.
, Rentería M.E.
, Trompet S.
, Arias-Vasquez A.
, Seshadri S.
, Desrivières S.
, et al.
Nature neuroscience, 2016 12; 19(12), p. 1569-1582.
PLD3 in Alzheimer's Disease: a Modest Effect as Revealed by Updated Association and Expression Analyses.
, Fan Y.
, Wang D.
, Bi R.
, Zhang C.
, Fang Y.
, Yao Y.G.
Molecular neurobiology, 2016 08; 53(6), p. 4034-4045.
Racial and age differences in colon examination surveillance following a diagnosis of colorectal cancer.
, Hensley Alford S.
, Kucera G.P.
, Fortman K.
, Ulcickas Yood M.
, Jankowski M.
, Johnson C.C.
Journal of the National Cancer Institute. Monographs, 2005; (35), p. 96-101.